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Abstract
Background: Poor adherence to highly active antiretroviral therapy (HAART) may result in treatment failure
and death. Most reports of the effect of adherence to HAART on mortality come from studies where special
efforts are made to provide HAART under ideal conditions. However, there are few reports of the impact of
non-adherence to HAART on mortality from community HIV/AIDS treatment and care programmes in
developing countries. We therefore conducted a study to assess the effect of adherence to HAART on survival
in The AIDS Support Organization (TASO) community HAART programme in Kampala, Uganda.
Methods: The study was a retrospective cohort of 897 patients who initiated HAART at TASO clinic, Kampala,
between May 2004 and December 2006. A total of 7,856 adherence assessments were performed on the data.
Adherence was assessed using a combination of self-report and pill count methods. Patients who took ≤ 95% of
their regimens were classified as non-adherent. The data was stratified at a CD4 count of 50 cells/mm3. Kaplan
Meier curves and Cox proportional hazards regression models were used in the analysis.
Results: A total of 701 (78.2%) patients had a mean adherence to ART of > 95%. The crude death rate was 12.2
deaths per 100 patient-years, with a rate of 42.5 deaths per 100 patient-years for non-adherent patients and 6.1
deaths per 100 patient-years for adherent patients. Non-adherence to ART was significantly associated with
mortality. Patients with a CD4 count of less than 50 cells/mm3 had a higher mortality (HR = 4.3; 95% CI: 2.22–
5.56) compared to patients with a CD4 count equal to or greater than 50 cells/mm3 (HR = 2.4; 95% CI: 1.79–2.38).
Conclusion: Our study showed that good adherence and improved survival are feasible in community HIV/AIDS
programmes such as that of TASO, Uganda. However, there is need to support community HAART programmes
to overcome the challenges of funding to provide sustainable supplies particularly of antiretroviral drugs; provision
of high quality clinical and laboratory support; and achieving a balance between expansion and quality of services.
Measures for the early identification and treatment of HIV infected people including home-based VCT and
HAART should be strengthened.
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Background
The introduction of HAART has greatly improved the sur-
vival of HIV/AIDS infected people. HAART reduces mor-
bidity and mortality by suppression of viral replication,
restoration and preservation of immune function, and
prevention of drug resistance [1-4]. Mortality among
patients on HAART is associated with high baseline levels
of HIV RNA [5]; WHO stage III or IV at the beginning of
treatment, low body mass index; severe anaemia; low
CD4 cell count [1,6]; type of ART treatment; cotrimoxa-
zole prophylaxis[7]; gender [8,9]; resource-poor settings
[10] and poor adherence to HAART [11-13].
Adherence to HAART is critical to the survival of HIV/
AIDS infected people. A pooled analysis of North Ameri-
can studies reported adherence of 55% (95% CI 49%–
62%) while for African studies adherence was 77% (95%
CI 68%–85%)[14]. Non adherence to HAART is a major
public health concern because it leads to virologic, immu-
nologic and clinical failure, and increases the risk of trans-
mission of drug resistant virus [15]. The major causes of
non adherence to HAART are forgetfulness, lack of under-
standing of treatment benefits, severity of adverse events,
and the level of complexity of the drug regimen[14].
Given this complexity, the effect of adherence to HAART
on survival has been reported mainly in clinical trials or
other controlled environments [1,3,12,16]. However, due
to the high demand for HAART, other avenues including
community HIV/AIDS treatment and care programmes
are increasingly being used to provide HAART. In Uganda,
The AIDS Support Organization (TASO) was established
in 1987 as the first indigenous non-governmental organi-
zation (NGO) in Africa to respond to the needs of people
living with HIV/AIDS. TASO's community HAART pro-
gramme was rolled out in May 2004, and by the end of
December 2005, the cumulative number of TASO clients
enrolled on HAART countrywide was 5,788 [17]. How-
ever, it is not known whether the TASO community
HAART programme confers survival benefits that are sim-
ilar to those reported in controlled or government set-
tings. We therefore conducted a study to determine the
effect of non adherence to HAART on survival in the TASO
community HIV/AIDS treatment and care programme,
Kampala, Uganda.
Methods
The study was carried out in The AIDS Support Organiza-
tion (TASO) Mulago clinic Kampala, Uganda. HIV/AIDS
patients are identified through voluntary counselling and
testing, and registered at TASO if found to be HIV positive.
The criteria for HAART entry are: a CD4 cell count below
200 cells/mm3; WHO stage 3 or 4 disease; or a history of
recurrent herpes zoster [18]. Before enrolment, the patient
is asked to identify a medicine companion who is nor-
mally a relative, friend, neighbour or spouse to help with
adherence, and to remind him/her to take the medicines.
After enrolment, the patient is given medicines for 3 days
and assessed for adherence. If he/she takes all the pills
over the three days, he/she is given medicines for 2 weeks.
If the adherence is still good at the end of the 2 weeks, he/
she is given drugs for 2 months and thereafter for 6
months. Patients who are found to have poor adherence
are given appointments for adherence counselling.
There are routine clinic visits after enrolment when
HAART drugs are dispensed and adherence assessed: at
two weeks; two months; and thereafter at six months. The
distribution of follow-ups depends on the patient's per-
formance in terms of improvement and adherence exhib-
ited. The follow-ups are carried out by trained and
experienced counsellors and field staff. TASO provides
medical care through its clinics which are held twice a
week. Pill count adherence is monitored by asking
patients to retain any missed doses in their pill boxes, and
pill boxes are checked when medicines are re-filled by the
home visitors for patients on the home care programme
and at the clinic for patients on the facility based treat-
ment and care programme. Adherence is assessed as pill
count (PCA) which is the number of pills actually taken as
a percentage of the number of pills delivered for the home
based treatment programme or dispensed for the facility
based programme. Self reported adherence measurement
technique is used by asking the patients the number of
times they have missed taking their pills. The adherence
levels from the two measures are compared. The higher
level is recorded as the patient's adherence level for that
assessment and the lower level, if less or equal to 95%,
forms the basis for the patient's follow up for adherence
support through adherence counselling.
All HIV/AIDS patients at TASO Mulago clinic, who were
aged at least 15 years, initiated antiretroviral treatment in
the period from May 2004 to December 2005, and whose
records were readily available, were included in this anal-
ysis. We used combined inferences from multiple imputa-
tions to impute for the missing data in the important
variables of study interest. The mean adherence to HAART
for each eligible record was computed and the records
were divided into two categories: adherent (average
adherence greater than 95%) and non-adherent (≤ 95%
adherence). Death was confirmed from death notification
filled by the TASO medical team. Analysis was based on
all-cause mortality.
Data was cleaned and coded using STATA release 9.0
(StataCorp, USA). Background characteristics between
adherent and non-adherent patients were compared by
logistic regression. The outcome of interest was survival
time as measured from the date of HAART initiation to theBMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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reported date of death for patients who died, or the date
of the last recorded visit for patients who were censored.
Kaplan Meier plots, and log rank tests were used to illus-
trate survival in different groups. Cox proportional haz-
ards regression models were used to investigate factors
associated with survival. Interactions between factors were
also investigated. Age, sex and predictor variables found
to be significant (p < 0.05) in univariable analyses were
considered as candidate regressors in the Cox models. The
proportional hazards assumption was tested using Sch-
oenfeld residuals.
Regulatory approvals
The study was approved by Makerere University Clinical
Epidemiology Unit (CEU), Makerere University Faculty of
Medicine Research and Ethics Committee, The AIDS Sup-
port Organisation (TASO) Research and Ethics Commit-
tee, and the Uganda National Council for Science and
Technology.
Role of the funding sources
The funding sources had no role in the design, conduct, or
reporting of the study findings or the decision to submit
the manuscript for publication.
Results
A total of 897 patients were eligible for the study and
7,856 adherence assessments were reviewed. Of these
assessments, 6,527 (83%) recorded adherence > 95%.
Out of the 897 patients studied, 196 (21.9%) patients had
a mean adherence of 95% or less, and 701 (78.2%)
patients had overall mean adherence of greater than 95%
(Table 1). The median number of adherence assessments
for non-adherent and adherent patients were 6.9 and 10.3
respectively.
The majority of the patients were females (75.3%), reflect-
ing TASO's patient distribution ratio of males to females
of approximately 1:3 (Table 2). The mean age at initiation
of HAART was 38.6 years (SD = 8.4) while the median age
was 37 years. The majority of the patients (78%) studied
were initiated on HAART with a baseline CD4 count of 50
cells/mm3 or more. Most patients (96.5%) had been mar-
ried while 82.5% had attained at least primary education.
The total patient-time contributed was 1,343.4 patient-
years. During the study period, 164 patients (18.3%) died
giving a crude death rate of 12.2 per 100 patient-years
(95% CI; 10.5–14.2) (Table 3). The maximum observed
exit time was approximately 2.6 years, and the last death
was observed at 2.3 years. For the non adherent patients,
94 deaths were reported, giving an overall mortality rate
of 43 deaths per 100 patient-years (95% CI: 35 – 52),
while for adherent patients 68 deaths were reported, giv-
ing a mortality rate of 6.1 deaths per 100 patient-years
(95% CI: 5 – 8). The patients lost to follow up were 147
(16.4%).
Table 1: Adherence to HAART among 897 patients in TASO Kampala, Uganda
Variable Category Total Adherent to HAART, n (%) 95% CI
Overall 897 701 (78.2) 75.3–80.8
Sex Male 222 166 (74.8) 68.5–80.3
Female 675 535 (79.3) 76.0–82.3
Age in years Less than 35 301 246 (81.7) 76.9–85.9
35 or more 596 455 (76.3) 72.7–79.7
Education None 157 111 (70.7) 62.9–77.7
Educated 740 590 (79.7) 76.6–82.6
Religion Catholic 274 212 (77.4) 72.0–82.2
Protestant 363 293 (80.7) 76.3–84.6
Pentecostal 143 106 (74.1) 66.1–81.1
Orthodox 54 42 (77.8) 64.4–88.0
Muslim 56 41 (73.2) 59.7–84.2
Other 7 7 (100) 100+
Married Ever 866 676 (78.1) 75.2–80.8
Never 31 25 (80.6) 62.5–92.5
CD4 count Less than 50 197 172 (87.3) 81.8–91.6
50 or more 700 529 (75.6) 72.2–78.7
+ One sided 97.5% CIBMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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Table 3 shows the unadjusted survival analyses for socio-
demographic and clinical characteristics. Better survival
(lower hazard) was seen for those with higher education
level (HR = 0.52, 95% CI 0.37–0.73), patients with base-
line CD4 count of above 50 cells/mm3 (HR = 0.29, 95%
CI 0.21–0.39), and those with >95% adherence (HR =
0.11, 95% CI 0.08–0.16). Kaplan Meier survival curves are
shown for the significant variables (Figure 1, 2, 3).
There was significant interaction between CD4 count at
initiation of HAART and adherence in their effect on sur-
vival (p < 0.001) (Table 4). In patients with CD4 count
less than 50 cells at HAART initiation, adherence showed
a 4-fold reduction in survival (HR 0.23, 95% CI 0.18–
0.45). In patients with CD4 count greater than or equal to
50 cells at HAART initiation, adherence showed a 2-fold
reduction in survival (HR 0.42, 95% CI 0.31–0.56). In
multivariate analysis, adherence to HAART was associated
with survival (HR 0.46, 95% CI 0.47–0.50) after control-
ling for age, sex and education level (Table 5).
Discussion and Conclusion
Our study showed that the majority of the patients attend-
ing TASO Mulago clinic, Kampala, had good adherence to
HAART with 78.2% of the patients achieving a mean
adherence of greater than 95%. Comparison of adherence
to HAART between studies is fraught with many obstacles
including differences in study population and design, def-
inition and measurement of adherence, as well as differ-
ences in sample size and type of HAART. Nevertheless, the
adherence rate in our study was similar to that reported in
previous studies in sub-Saharan Africa [14]. The high
adherence rate to HAART observed in TASO is remarkable
considering that its HAART programme is in a non
research or government setting. The high adherence to
HAART can be attributed to the continuity of care and
close support of the patients that is the hallmark of TASO
and which has also been described elsewhere [19]. TASO
originated as a patient-centred care and support organiza-
tion and this philosophy has persisted even after the intro-
duction of HAART.
The overall mortality was 12 per 100 person-years but the
estimate may have been affected by four major factors.
Compared to settings where HAART is initiated at CD4
counts of <350 cells/mm3 the patients in our study were
initiated late on HAART (<200 cells/mm3), though it is
the policy of Ministry of Health. This late initiation on
HAART may have increased the mortality in our study. We
also excluded participants who had been on HAART for
less than one year in an effort to capture mortality that
occurred only after HAART was deemed to be effective. By
so doing however we may have inadvertently excluded
early mortality and yet several studies have reported that
mortality among HAART patients is greatest in the first
three months of treatment [3,10,20]. Thus exclusion of
Table 2: Background and clinical characteristics of 897 patients on HAART in TASO Kampala, Uganda
Variable Non Adherent n (%) Adherent to HAART, n (%) Odds Ratio 95% CI
Sex
Male 56 (28.6) 166 (23.7) 1.0
Female 140 (71.4) 535 (76.3) 0.77 0.54–1.11
Age in median years 36 37 N/A N/A
Education
None 46 (23.5) 111 (15.8) 1.0
Educated 150 (76.5) 590 (84.2) 0.61 0.42–0.90
Religion
Catholic 62 (31.6) 212 (30.2) 1.0
Protestant 70 (35.7) 293 (41.8) 1.25 0.65–2.41
Pentecostal 37 (18.9) 106 (15.1) 1.19 0.75–1.91
Orthodox 12 (6.1) 42 (6.0) 0.98 0.48–1.97
Muslim 15 (7.7) 41 (5.9) 0.82 0.56–1.20
Other 0 (0.0) 7 (1.0) - -
Married
Ever 190 (96.9) 676 (96.4) 1.0
Never 6 (3.1) 25 (3.6) 1.17 0.47–2.90
CD4 count
Less than 50 25 (12.8) 172 (24.5) 1.0
50 or more 171 (87.2) 529 (75.5) 2.22 1.41–3.50BMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
Page 5 of 10
(page number not for citation purposes)
early mortality may have led to an underestimate of over-
all mortality in our study.
In our study, there were difficulties in ascertaining the
cause of death. The cause of death was determined by the
TASO medical team and was mostly in the form of verbal
autopsy which classifies deaths in broad categories but
does not permit assignment of a specific cause of death
[21]. Thus there were limitations in determining the
underlying cause of death and we therefore performed all-
cause mortality analysis. The use of all-cause mortality in
our study may have led to an under or overestimation of
the overall mortality among HAART patients. The use of
the multiple imputation method to impute missing data
may also have distorted our estimates if the missing data
were not random[22]. Finally, under or overestimation of
mortality could have occurred because a significant pro-
portion (16.4%) of the participants on HAART were lost
to follow up. Nevertheless, the overall mortality in our
study was similar to that reported in previous studies
[10,20,23-28].
Non-adherent participants had a mortality of 42.5 deaths
per 100 person-years and, after adjusting for age, sex and
education level, were two times as likely to die as adherent
participants. These findings are consistent with other
studies that have reported that non-adherence is associ-
ated with increased mortality [12,27,29]. Non adherence
to HAART leads to virologic, immunologic and clinical
failure that is mediated mainly by two potentially re-
enforcing mechanisms. Non-adherence to HAART leads
to failure to suppress viral replication, thus increasing the
likelihood of developing HIV mutations that could lead to
the development of drug-resistant viral strains. Secondly,
non-adherence to HAART fails to prevent further viral
destruction of the cellular immune system with conse-
quent reduction in the level of CD4+ cells and develop-
ment of opportunistic infections [15]. It is worth noting
Table 3: Unadjusted analysis of mortality according to adherence and other characteristics among 897 patients in TASO Kampala, 
Uganda
Variable Total Deaths Total Patient-years (Death rate/100 Patient-years) HR 95% CI
Overall 164 1343.4 (12.2) - 10.5–14.2
Sex
Male 34 333.6 (10.2) 1.0
Female 130 1009.8 (12.9) 1.26 0.86–1.83
Age in years
Less than 35 56 462.4 (12.1) 1.0
35 or more 108 881.0 (12.3) 1.04 0.75–1.44
Education
None 45 224.1 (20.1) 1.0
Educated 119 1119.3 (10.6) 0.52 0.37–0.73
Religion
Catholic 55 408.6 (13.5) 1.0
Protestant 63 543.2 (11.6) 0.88 0.61–1.26
Pentecostal 29 216.5 (13.4) 1.01 0.65–1.59
Orthodox 9 82.3 (10.9) 0.82 0.40–1.65
Muslim 8 82.6 (9.7) 0.78 0.37–1.63
Other 0 10.6 (0.0) - -
Married
Never 5 46.7 (10.7) 1.0
Ever 159 1296.7 (12.3) 1.20 0.49–2.93
CD4 count
Less than 50 86 306.7 (28.0) 1.0
50 or more 78 1036.6 (7.5) 0.29 0.21–0.39
Adherence
Non adherence 94 226.0 (42.5) 1.0
Adherence 68 1117.3 (6.1) 0.11 0.08–0.16BMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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that mortality among adherent participants in our study
(6.1 per 100 person-years) was comparable to mortality
rates reported in developed world settings.
In our study we found overwhelming evidence of a statis-
tical interaction between baseline CD4 count and non-
adherence i.e. baseline CD4 count modified the effect of
non-adherence. In patients with a CD4 count <50 cells/
mm3 non-adherence increased the risk of mortality four
fold, whereas in patients with a CD4 count of 50 cells/
mm3 or above at baseline, non-adherence doubled the
risk of mortality. Previous studies have reported that CD4
counts at the initiation of HAART independently modify
survival with decrease in CD4 count being associated with
increased mortality [3,6,12,27]. Although Nachega et al
reported that there was no interaction between adherence
and baseline CD4 count, they found that CD4 count
strongly modified the effect of adherence on survival, with
the greatest mortality (HR 4.54, 95% CI: 2.83–7.29)
occurring in the most immunosuppressed patients (≤ 50
cell/μL.
The findings of this analysis have important policy impli-
cations particularly for HAART programmes in developing
countries. Our study has shown that good adherence to
HAART and improved HIV survival are feasible in a com-
munity HIV/AIDS treatment and care programme.
Uganda, like many developing countries, has limited
capacity to provide HAART through the government
health care system. Accordingly, there is increasing need
to provide HAART through non governmental pro-
grammes including home or community care pro-
grammes. As of June 2007, of the more than 100,000
people in Uganda taking HAART, 14% received their
drugs through home or community care programmes,
mostly through TASO.
The success of the TASO community HAART programme
can be attributed to a number of factors including the per-
sonalized patient-centred approach; the continuity of care
and follow up through home visits; total patient and fam-
ily care and support; and free access to services. These fac-
tors have contributed to the high adherence rates in TASO
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by Adherence status Figure 1
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by 
Adherence status.BMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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that are critical for improved survival of HIV infected peo-
ple. The major challenges of the TASO community
HAART programme include the provision of high quality
clinical and laboratory services (e.g. CD4 cell counts) to
support HAART; funding to provide sustainable provision
of antiretroviral drugs and other supplies; and the need to
balance the expansion of the TASO community HAART
programme to meet increasing demand without losing
the personal touch that has over the years ensured the
quality of services and success of TASO.
Our study highlighted the poorer outcomes in HIV
infected people with low CD4 counts and echoes the need
to identify and treat eligible HIV infected people early and
for intensive adherence interventions to target HIV-1
infected patients with the lowest CD4 counts [16]. The
home-based VCT programme that is also offered in TASO
is one way in which HIV infected people can be identified
early so that they benefit maximally from HAART.
The principal limitation of our study was the study design.
The study was a retrospective cohort, and therefore we did
not control for all the potential confounders that could
confound the association between non-adherence to
antiretroviral therapy and patients' survival, such as viral
load and opportunistic infections at initiation of HAART.
Viral loads were not recorded by TASO, while there was no
precise information on opportunistic infections at the
time of initiation of antiretroviral therapy. This situation
may have resulted in an under or over estimate of the
association between non adherence and survival. How-
ever, random error was unlikely to have biased our find-
ings because the study needed to observe 121 deaths to
show a significant effect in survival but we observed 164
deaths.
The measurement and definition of adherence to antiret-
roviral therapy may have introduced bias. There is no gold
standard for measuring adherence to antiretroviral ther-
apy [14]. The approaches employed in this study included
patient self-report and pill counts. The self-report obtains
a patient's subjective evaluation of his or her own level of
treatment compliance behaviour. The advantages of the
self-report method include its simplicity, speed, and via-
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by CD4 count at ini- tiation Figure 2
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by 
CD4 count at initiation.BMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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bility of use. The disadvantages include reliance on recall
and social desirability bias, with a tendency to overesti-
mate adherence. Nevertheless, several studies highlight
the usefulness of the self-report as an adherence measure-
ment tool and show it to correlate well to virologic out-
come [30,31]. Adherence measurement depended on a
clinician's subjective judgment. Also using mean adher-
ence over the period a patient was on treatment could
have introduced measurement bias into our study.
In our study, the adherence assessments for non-adherent
and adherent patients were unequal. One interpretation
of this finding is that unequal assessment of adherence
between the adherent and the non adherent patients may
have introduced bias in our estimates. However, an alter-
native and more plausible explanation is that differences
in adherence levels between patients especially in the
clinic-based programme may instead have lead to differ-
ences in adherence assessments between the adherent and
non adherent patients since the adherence assessments
were based on patient visits to the TASO clinic. The type
of regimen patients were taking could have had an impact
on their survival and hence distorted our estimates. As
already mentioned, we could not control for the type of
regimen patients were taking. While our findings may
have been affected by such factors, we believe that our
overall conclusions are robust.
In conclusion, our study showed that good adherence to
HAART and improved survival are feasible in community
HIV/AIDS treatment and care programmes such as that of
TASO, Uganda. However, there is need to support com-
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by Education status Figure 3
Kaplan Meier survival estimates in 897 HIV/AIDS patients initiated on HAART in TASO Kampala, Uganda, by 
Education status.
Table 4: Interaction between CD4 count at HAART initiation and adherence among 897 HIV/AIDS patients in TASO Kampala, 
Uganda
Variable CD4 count (cells) Hazard Ratio 95% CI
Adherence >95% <50 0.23 0.18–0.45
Adherence >95% ≥ 50 0.42 0.31–0.56
Likelihood ratio test was significant (p < 0.001)BMC Health Services Research 2008, 8:241 http://www.biomedcentral.com/1472-6963/8/241
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munity HIV/AIDS HAART programmes to overcome the
challenges of funding to provide sustainable supplies par-
ticularly of antiretroviral drugs; provision of high quality
clinical and laboratory support; and achieving a balance
between expansion and maintenance of quality of serv-
ices. Measures for early identification and treatment of
HIV infected people including home-based VCT and
HAART should be strengthened.
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